Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2,2'-Dithiodiethanesulfonic Acid SCHEMBL32679299 | 0.97 | PTGS1 (0.43) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| 2,2'-Dithiodiethanesulfonic Acid SCHEMBL30887006 | 0.97 | PTGS1 (0.43) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| 2,2'-Dithiodiethanesulfonic Acid SCHEMBL29061145 | 0.97 | PTGS1 (0.43) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| 2,2'-Dithiodiethanesulfonic Acid SCHEMBL747638 | 0.97 | PTGS1 (0.43) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| 2,2'-Dithiodiethanesulfonic Acid SCHEMBL836069 | 0.97 | PTGS1 (0.43) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| 2,2'-Dithiodiethanesulfonic Acid SCHEMBL8403166 | 0.97 | PTGS1 (0.43) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| 2,2'-Dithiodiethanesulfonic Acid SCHEMBL7864315 | 0.97 | PTGS1 (0.43) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| 2,2'-Dithiodiethanesulfonic Acid SCHEMBL834156 | 0.84 | LMNA (0.35) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| 2,2'-Dithiodiethanesulfonic Acid SCHEMBL834581 | 0.84 | KDM4E (0.39) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| 2,2'-Dithiodiethanesulfonic Acid SCHEMBL7050821 | 0.84 | KDM4E (0.39) | PTGS1PDE4ALMNASLC6A6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230220481-A1 | Method for Determining Sensitivity to 2,2'-Dithio-bis-Ethane Sulfonate | LANTERN PHARMA INC. | 2023-07-13 | — | — | US | claimed |
| CN-115397405-A | Method for determining sensitivity to 2,2' -dithiobisethane sulfonate | 蓝腾制药公司 | 2022-11-25 | — | — | CN | claimed |
| EP-4087609-A1 | METHOD FOR DETERMINING SENSITIVITY TO 2,2'-DITHIO-BIS-ETHANE SULFONATE | Lantern Pharma Inc. (US) | 2022-11-16 | — | — | EP | claimed |
| US-20220168258-A1 | METHOD FOR TREATING FEMALE NON-SMOKERS WITH NON-SMALL CELL LUNG CANCER | LANTERN PHARMA INC (US) | 2022-06-02 | — | — | US | claimed |
| EP-3935043-A1 | METHOD FOR TREATING FEMALE NON-SMOKERS WITH NON-SMALL CELL LUNG CANCER | Lantern Pharma Inc. (US) | 2022-01-12 | — | — | EP | claimed |
| CN-113906010-A | Method of treating female non-smokers with non-small cell lung cancer | 蓝腾制药公司 | 2022-01-07 | — | — | CN | claimed |
| WO-2021142460-A1 | METHOD FOR DETERMINING SENSITIVITY TO 2,2'-DITHIO-BIS-ETHANE SULFONATE | LANTERN PHARMA INC. (US) | 2021-07-15 | — | — | WO | claimed |
| WO-2020185640-A1 | METHOD FOR TREATING FEMALE NON-SMOKERS WITH NON-SMALL CELL LUNG CANCER | LANTERN PHARMA INC. (US) | 2020-09-17 | — | — | WO | claimed |
| US-10010618-B2 | Methods for treating cancer using combination therapies | ENDOCYTE, INC. (US) | 2018-07-03 | — | — | US | claimed |
| US-20170007561-A1 | CONTEMPORANEOUS, HETEROGENEOUSLY-ORIENTED, MULTI-TARGETED THERAPEUTIC MODIFICATION AND/OR MODULATION OF DISEASE BY ADMINISTRATION OF SULFUR-CONTAINING, AMINO ACID-SPECIFIC SMALL MOLECULES | BIONUMERIK PHARMACEUTICALS, INC. | 2017-01-12 | — | — | US | claimed |
| US-20030203960-A1 | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity | LANTERN PHARMA INC. | 2003-10-30 | — | — | US | claimed |
| EP-0792154-B1 | COMPOSITION OF CISPLATIN IN COMBINATION WITH 2,2'-DITHIO-BIS(ETHANESULFONATE) (DIMESNA) | BIONUMERIK PHARMACEUTICALS INC (US) | 2003-04-16 | — | — | EP | claimed |
| US-5902610-A | ADMINISTERING WITH OR WITHOUT CISPLATIN IN THE SAME FORMULATION, TO REDUCE TOXIC SIDE EFFECTS OF CISPLATIN IN CANCER THERAPY AND POTENTIATE ITS ANTITUMOR ACTIVITY | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-05-11 | — | — | US | claimed |
| US-5866617-A | AQUEOUS SOLUTION FOR ADMINISTRATION TO PATIENTS ALSO RECEIVING CISPLATIN; REDUCED SIDE EFFECTS, INCREASED ANTITUMOR ACTIVITY | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-02-02 | — | — | US | claimed |
| US-5866615-A | LYOPHILIZED FORMULATION WITH ANTICANCER AGENTS; REDUCED SIDE EFFECTS, INCREASED ACTIVITY | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-02-02 | — | — | US | claimed |
| US-5866169-A | LYOPHILIZED FORMULATION WITH CISPLATIN; REDUCED SIDE EFFECTS, INCREASED ANTITUMOR ACTIVITY | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-02-02 | — | — | US | claimed |
| US-5789000-A | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1998-08-04 | — | — | US | claimed |
| EP-0792154-A1 | COMPOSITION OF CISPLATIN IN COMBINATION WITH 2,2'-DITHIO-BIS(ETHANESULFONATE) (DIMESNA) | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1997-09-03 | — | — | EP | claimed |
| WO-1996014852-A1 | COMPOSITION OF CISPLATIN IN COMBINATION WITH 2,2'-DITHIO-BIS(ETHANESULFONATE) (DIMESNA) | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1996-05-23 | — | — | WO | claimed |
| EP-0003750-B1 | SALTS OF DITHIODIALKANESULFONIC ACIDS FOR USE IN CYTOSTATIC THERAPY WITH ALKYLATING AGENTS | Asta-Werke Aktiengesellschaft Chemische Fabrik (DE) | 1981-04-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170007561-A1 | CONTEMPORANEOUS, HETEROGENEOUSLY-ORIENTED, MULTI-TARGETED THERAPEUTIC MODIFICATION AND/OR MODULATION OF DISEASE BY ADMINISTRATION OF SULFUR-CONTAINING, AMINO ACID-SPECIFIC SMALL MOLECULES | ROS1, MET, IGF1R | PTGS1 1074/4885PDE4A 4595/4885LMNA 3300/4885 |
| US-10010618-B2 | Methods for treating cancer using combination therapies | SLC7A11, CXCR2, TPX2 | PTGS1 304/4885PDE4A 3404/4885LMNA 4453/4885 |
| US-20220168258-A1 | METHOD FOR TREATING FEMALE NON-SMOKERS WITH NON-SMALL CELL LUNG CANCER | TST, CTH, SPTAN1 | PTGS1 1071/4885PDE4A 2965/4885LMNA 3986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.